End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4384 USD | +2.62% | +3.89% | -10.00% |
30/04 | Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product | CI |
30/04 | Akili, Inc. to Reduce Workforce | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
-10.00% | 34.46M | |
+11.29% | 225B | |
+8.76% | 186B | |
+12.90% | 135B | |
+25.95% | 107B | |
+0.15% | 63.56B | |
+11.08% | 51.04B | |
+5.62% | 51.32B | |
+6.28% | 43.3B | |
+4.80% | 36.99B |
- Stock Market
- Equities
- AKLI Stock
- News Akili, Inc.
- Morgan Stanley Initiates Akili at Equalweight, $2 Price Target, Cites Uncertainties Regarding EndeavorRx's Launch